Article révisé par les pairs
Titre:
  • Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Auteur:Hadji, Peyman; Aapro, Matty; Al-Dagri, Nasser; Alokail, Majed; Biver, Emmanuel; Body, Jean-Jacques; Brandi, M.L.; Brown, Janet; Confavreux, Cyrille; Cortet, Bernard; Drake, Matthew; Ebeling, Peter R; Eriksen, Erik Fink; Fuleihan, Ghada El Hajj; Guise, Theresa; Harvey, Nicholas N.C.; Kurth, Andreas; Langdahl, Bente; Lems, Willem Frederik; Matijevic, Radmila; Mccloskey, Eugene; Nappi, Rossella R.E.; Palacios, Santiago; Pfeiler, Georg; Reginster, Jean-Yves; Rizzoli, René; Santini, Daniele; Tuzun, Sansin; Poznak, Catherine Van; Villiers, Tobias De; Zillikens, Maria Carola Carola M.C.; Coleman, Robert
Informations sur la publication:Journal of Bone Oncology, 53, 100694
Statut de publication:Publié, 2025-08
Sujet CREF:Biopsychologie et psychopathologie
Neurosciences cognitives
Mots-clés:Aromatase Inhibitor
Bisphosphonate
Breast cancer
Denosumab
Fracture
Osteoporosis
Note générale:SCOPUS: re.j
Langue:Anglais
Identificateurs:urn:issn:2212-1374
info:doi/10.1016/j.jbo.2025.100694
info:pii/S2212137425000351
info:scp/105010883671

Documents en relation

DI-fusion